On Ori Spotlight episode eight we sat down with Robert Preti, strategic advisor at Ori.
Robert has an illustrious background in cell and gene therapy leading innovation as Chief Strategy Officer for Minaris as well as leading the Alliance for Regenerative Medicine (ARM) for several years as chairman.
Joining Ori Biotech's CEO Jason C. Foster, the pair discuss where cell therapy all began, its explosion into the biopharma industry scene and why there is still a lot of work today to make sure that as many patients as possible can benefit from its life-changing possibilities.
Learn more about Robert Preti | https://www.linkedin.com/in/robert-preti-41586217/
D'autres épisodes de "Ori Spotlight"
Kevin Kyle and Carol Houts - Germfree
49:37For episode 16 of the Ori Spotlight Podcast, Jason C. Foster is joined by Germfree CEO, Kevin Kyle and VP of Regulatory and Business Development, Carol Houts. Germfree specializes in the manufacture of mobile and modular cleanrooms, laboratory equipment, cGMP facilities and biosafety labs to deliver solutions across the life science spectrum. Together they sat down to explore how Germfree supported the industry through COVID-19 - adapting with innovation within decentralized manufacturing of cell therapy, and taking an ecosystem approach to address supply chain challenges. Learn more about Kevin Kyle: https://www.linkedin.com/in/kevin-kyle-1b9b39/ | Carol Houts: https://www.linkedin.com/in/carol-houts-46a628a/
Jo Anne Valentino - Chief Operating Officer, Minaris Regenerative Medicine
44:52For episode 15 of Ori Spotlight, Jason C. Foster is joined by Jo Anne Valentino, Chief Operating Officer at Minaris Regenerative Medicine as she shares her insights into cell and gene therapy development. Jo Anne has extensive experience in pharmaceutical manufacturing, having previously held senior positions at Merck and Novartis. Minaris Regenerative Medicine is a CDMO dedicated to the production of CGT products, offering high-quality clinical and commercial manufacturing services, developmental solutions and technologies. Together, Jason and Jo Anne discuss how digital transformation can support scalability within CGT manufacturing, what can be learned from pharmaceutical supply chains, and the challenges faced within the CDMO industry. Learn more about Jo Anne: https://www.linkedin.com/in/jo-anne-valentino/
Ne ratez aucun épisode de “Ori Spotlight” et abonnez-vous gratuitement à ce podcast dans l'application GetPodcast.
John Connolly - Chief Scientific Officer, Parker Institute for Cancer Immunotherapy
45:28In episode 14 of the Ori Spotlight Podcast, Jason C. Foster is joined by John Connolly, Chief Scientific Officer at the Parker Institute for Cancer Immunotherapy, who explained why and how the industry needs to increase the accessibility of CGT for patients. The Parker Institute is a research institute on a mission – to break down infrastructure barriers that have slowed progress in the development of immunotherapies. Their infrastructure builds collaboration between researchers, non-profits and industry organizations to bring treatments to patients faster. John sat down with Jason to discuss the value of academia and industry collaborations, the importance of flexibility and scalability in CGT manufacturing, and how as an industry we should measure the success of CGT. Learn more about John Connolly: https://www.linkedin.com/in/john-connolly-205b337/
Mike Nicholson & Matt Haines - Inceptor Bio
47:03In episode 13 of the Ori Spotlight Podcast Jason C. Foster sits down with Mike Nicholson (President and Chief Operating Officer) and Matt Haines (Vice President of Manufacturing Operations) at Inceptor Bio, as they share their insights into the cell and gene therapy space. Inceptor Bio is on a mission to cure difficult to treat cancers using next-generation cell therapy platforms. Their unique partnership model, with university oncology research programs, leverages their manufacturing resources and expert cell and gene therapy skills, to advance therapeutics into the clinic. Mike and Matt catch up with Jason to discuss the opportunities and challenges of CGT manufacturing, bringing CGT to patients at scale and what they envision for the future of CGT. Learn more about: Mike Nicholson - LinkedIn | Matt Haines - LinkedIn
Adam Wieschhaus and Shaan Gandhi - Directors, Northpond Ventures
50:22In Episode 12 of the Ori Spotlight Podcast, Jason C. Foster sits down with Northpond Ventures, investor in both Ori’s Series A and Series B funding. We caught up with Directors Adam Wieschhaus and Shaan Gandhi, as they share their insights into the cell and gene therapy space. Northpond Ventures is a $2.15 billion venture capitalist firm focused on life science, medicine, and technology; with 60 investments to date since its inception. Adam and Shaan lead their San Francisco and Boston offices respectively. Adam and Shaan sit down with Jason to discuss why bringing scalable cell and gene therapies to market is vital, the impact these therapies have on patients, and what excites them most about the investments made within the CGT space. Learn more about: Adam Wieschhaus | https://www.linkedin.com/in/adamwieschhaus/ Shaan Gandhi | https://www.linkedin.com/in/shaangandhi/
Paul Meister - Partner, Novalis LifeSciences
41:31In episode 11 of the Ori Spotlight Podcast we sit down with Paul Meister, Partner at Novalis LifeSciences - lead investor of Ori Biotech’s series B round - as he shares his perspectives on the potential for CGT. Paul has extensive experience across the pharmaceutical, biotech and life science fields, having orchestrated the merger of Thermo Electron and Fisher Scientific before becoming chair of Thermo Fisher and, later, chair and CEO of Syneos Health. In this episode, he catches up with Jason C. Foster following the closure of Ori’s $101 million series B round, to explain why he decided to join us on our mission to enable widespread patient access to CGTs and what excites him most about our partnership.
Dr. Farlan Veraitch - Co-Founder and Chief Scientific Officer, Ori Biotech
45:44In episode 10 of the Ori Spotlight Podcast we sit down with Farlan Veraitch, Co-Founder and Chief Scientific Officer at Ori Biotech. Farlan is an internationally recognized expert in CGT-manufacturing, with 15 years’ experience as a leading academic at University College London, pioneering innovative technologies in CGT bioprocessing. At Ori, he leads the research and development of Ori's revolutionary manufacturing technology platforms. In the podcast, Farlan joins Jason C. Foster to share his co-founder story and explains Ori's unique approach, borne out of a desire to dramatically bring down the cost of CGTs and enable widespread patient access of these life-changing therapies. Learn more about Farlan | https://www.linkedin.com/in/farlan-veraitch-a677112/
Dr. Qasim Rafiq - Associate Professor of Cell and Gene Therapy Bioprocessing, University College London
42:46On episode nine of the Ori Spotlight Podcast we sat down with Qasim Rafiq, Associate Professor of Cell and Gene Therapy Bioprocessing at University College London, and Thomas Heathman, Ori's Vice President of Commercial Operations. Qasim leads the world first MSc in Manufacturing and Commercialization of Stem Cell and Gene Therapies, and was named as one of the top 20 influential and inspirational individuals in Advanced Medicine for 2020 by The Medicine Maker. Together, we explore one of the most significant factors affecting the high costs of CGT: the industry's ongoing talent shortage. They discuss how the problem should be addressed, bringing together academic institutions with CGT organizations to identify the evolving expertise required, not just across scientific and clinical research teams but also in digital and technology disciplines. Learn more about Dr. Qasim Rafiq| https://www.linkedin.com/in/qrafiq/?originalSubdomain=uk
Robert Preti, PhD - Strategic Advisor, Ori Biotech
52:22On Ori Spotlight episode eight we sat down with Robert Preti, strategic advisor at Ori. Robert has an illustrious background in cell and gene therapy leading innovation as Chief Strategy Officer for Minaris as well as leading the Alliance for Regenerative Medicine (ARM) for several years as chairman. Joining Ori Biotech's CEO Jason C. Foster, the pair discuss where cell therapy all began, its explosion into the biopharma industry scene and why there is still a lot of work today to make sure that as many patients as possible can benefit from its life-changing possibilities. Learn more about Robert Preti | https://www.linkedin.com/in/robert-preti-41586217/
Dr. Annalisa Jenkins - Strategic Advisor, Ori Biotech
48:25On episode seven of the Ori Spotlight Podcast we sat down with Dr. Annalisa Jenkins, Strategic Advisor for Ori and advisor to the FDA, to discuss the changes she's seen in CGT pricing and market access models over the years. As board chairman for many private and public companies, Annalisa recounts how it all started and how she sees the industry evolving. She's passionate about the idea that we need to continue to embrace innovation to drive down prices while still having successful companies that can meet the needs of both their patients and shareholders. Learn more about Dr. Annalisa Jenkins|